These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

584 related articles for article (PubMed ID: 36215392)

  • 41. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.
    Maneikis K; Šablauskas K; Ringelevičiūtė U; Vaitekėnaitė V; Čekauskienė R; Kryžauskaitė L; Naumovas D; Banys V; Pečeliūnas V; Beinortas T; Griškevičius L
    Lancet Haematol; 2021 Aug; 8(8):e583-e592. PubMed ID: 34224668
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Evaluation of neutrophil-to-lymphocyte ratio and immune response in patients vaccinated with Pfizer-Biontech vaccine.
    Mediu R; Rama A; Puca E
    J Infect Dev Ctries; 2022 May; 16(5):745-751. PubMed ID: 35656943
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Evaluation of response to different COVID-19 vaccines in vaccinated healthcare workers in a single center in Iran.
    Pourakbari B; Mirbeyk M; Mahmoudi S; Hosseinpour Sadeghi RH; Rezaei N; Ghasemi R; Esfandiari F; Mamishi S
    J Med Virol; 2022 Dec; 94(12):5669-5677. PubMed ID: 35883215
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The Effect of Age, Gender and Comorbidities Upon SARS-CoV-2 Spike Antibody Induction After Two Doses of Sinopharm Vaccine and the Effect of a Pfizer/BioNtech Booster Vaccine.
    Farid E; Herrera-Uribe J; Stevenson NJ
    Front Immunol; 2022; 13():817597. PubMed ID: 35711448
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The role of neutralizing antibodies by sVNT after two doses of BNT162b2 mRNA vaccine in a cohort of Italian healthcare workers.
    Infantino M; Manfredi M; Stacchini L; Cosma C; Grossi V; Lari B; Russo E; Amedei A; Benucci M; Veneziani F; Casprini P; Catalano CM; Cirrincione G; Bonaccorsi G; Pompetti A
    Clin Chem Lab Med; 2022 May; 60(6):934-940. PubMed ID: 35303766
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Assessing humoral immune response after two doses of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthcare workers.
    Demirbakan H; Koçer I; Erdoğan M; Bayram A
    Public Health; 2022 Apr; 205():1-5. PubMed ID: 35219127
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Investigation of an outbreak of symptomatic SARS-CoV-2 VOC 202012/01-lineage B.1.1.7 infection in healthcare workers, Italy.
    Loconsole D; Sallustio A; Accogli M; Leaci A; Sanguedolce A; Parisi A; Chironna M
    Clin Microbiol Infect; 2021 Aug; 27(8):1174.e1-1174.e4. PubMed ID: 33984489
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Antibody Avidity and Neutralizing Response against SARS-CoV-2 Omicron Variant after Infection or Vaccination.
    Dapporto F; Marchi S; Leonardi M; Piu P; Lovreglio P; Decaro N; Buonvino N; Stufano A; Lorusso E; Bombardieri E; Ruello A; Viviani S; Molesti E; Trombetta CM; Manenti A; Montomoli E
    J Immunol Res; 2022; 2022():4813199. PubMed ID: 36093434
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Response and Duration of Serum Anti-SARS-CoV-2 Antibodies After Inactivated Vaccination Within 160 Days.
    Xu QY; Xue JH; Xiao Y; Jia ZJ; Wu MJ; Liu YY; Li WL; Liang XM; Yang TC
    Front Immunol; 2021; 12():786554. PubMed ID: 35003104
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Inactive SARS-CoV-2 vaccine generates high antibody responses in healthcare workers with and without prior infection.
    Dinc HO; Saltoglu N; Can G; Balkan II; Budak B; Ozbey D; Caglar B; Karaali R; Mete B; Tuyji Tok Y; Ersoy Y; Ahmet Kuskucu M; Midilli K; Ergin S; Kocazeybek BS
    Vaccine; 2022 Jan; 40(1):52-58. PubMed ID: 34839992
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Primary SARS-CoV-2 Infections, Re-infections and Vaccine Effectiveness during the Omicron Transmission Period in Healthcare Workers of Trieste and Gorizia (Northeast Italy), 1 December 2021-31 May 2022.
    Cegolon L; Negro C; Mastrangelo G; Filon FL;
    Viruses; 2022 Nov; 14(12):. PubMed ID: 36560692
    [No Abstract]   [Full Text] [Related]  

  • 52. The level of protective post-vaccination antibodies in NIPH-NIH employees after administration of Pfizer vaccine against COVID-19.
    Rastawicki W; Płaza K
    Przegl Epidemiol; 2021; 75(1):3-13. PubMed ID: 34328282
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Waning immunity to inactive SARS-CoV-2 vaccine in healthcare workers: booster required.
    Balkan İİ; Dinc HO; Can G; Karaali R; Ozbey D; Caglar B; Beytur AN; Keskin E; Budak B; Aydogan O; Mete B; Ergin S; Kocazeybek B; Saltoglu N
    Ir J Med Sci; 2023 Feb; 192(1):19-25. PubMed ID: 35344137
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Antibody Responses to the BNT162b2 mRNA Vaccine in Healthcare Workers in a General Hospital in Japan: A Comparison of Two Assays for Anti-spike Protein Immunoglobulin G.
    Hibino M; Watanabe S; Kamada R; Tobe S; Maeda K; Horiuchi S; Kondo T
    Intern Med; 2022 Mar; 61(6):811-819. PubMed ID: 34980798
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A cross-sectional study of SARS-CoV-2 antibodies among healthcare workers in a tertiary care hospital in Taiwan: implications for protection against the Omicron variants.
    Chen CH; Chao DY; Kor CT; Kuo SF; Lin JS; Lai HW; Liu YT; Lin CH; Chen MK
    BMC Infect Dis; 2024 May; 24(1):529. PubMed ID: 38802771
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Investigation of Humoral and Cellular Immunity in TOBB ETÜ Hospital Workers After Three Doses of CoronaVac Vaccination and after One Dose of Comirnaty Vaccination Following Two Doses of CoronaVac].
    Özyurda F; Ardıçoğlu Akışın Y; Mert T; Poyraz B; Özkan Y; Turan M; Göçmen JS; Yücel A; Akar N
    Mikrobiyol Bul; 2022 Jul; 56(3):387-403. PubMed ID: 35960233
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Seroprevalence of SARS-CoV-2 anti-spike IgG antibody among COVID-19 vaccinated individuals residing in Surabaya, East Java, Indonesia.
    Megasari NLA; Yamani LN; Juniastuti J; Lusida MI; Mori Y
    PeerJ; 2023; 11():e16142. PubMed ID: 37780375
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Long-Term Kinetics of SARS-CoV-2 Antibodies and Impact of Inactivated Vaccine on SARS-CoV-2 Antibodies Based on a COVID-19 Patients Cohort.
    Zhang S; Xu K; Li C; Zhou L; Kong X; Peng J; Zhu F; Bao C; Jin H; Gao Q; Zhao X; Zhu L
    Front Immunol; 2022; 13():829665. PubMed ID: 35154152
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
    Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
    Front Immunol; 2021; 12():802858. PubMed ID: 35003131
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Robust humoral and cellular immune responses in long-term convalescent COVID-19 individuals following one-dose SARS-CoV-2 inactivated vaccination.
    Liang B; Xiang T; Wang H; Li Z; Quan X; Feng X; Li S; Lu S; Fan L; Xu L; Wang T; Wang X; Zhu B; Wang J; Yang D; Liu J; Zheng X
    Front Immunol; 2022; 13():966098. PubMed ID: 35979361
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.